How Fucoidan Is Easing Chemotherapy Side Effects
Ask any oncology nurse what the hardest part of treatment is for patients, and chemotherapy itself is only half the answer. The other half is what comes after: the numbness in the fingertips that makes buttoning a shirt difficult, the tingling that keeps someone up at night, the fatigue that outlasts the infusion by weeks. Chemotherapy-induced peripheral neuropathy, or CIPN, affects a significant share of patients on common regimens, and for a long time, oncology hasn't had much to offer beyond dose adjustments and waiting it out.
That's part of why a handful of 2025 studies
on fucoidan caught the attention of researchers working in supportive and
integrative oncology. Published work has begun to map how this marine sulfated
polysaccharide interacts with the biological pathways behind CIPN — including
research describing how fucoidan reduced the accumulation of neutrophil
extracellular traps, a known driver of nerve inflammation, and separate work
identifying its activation of the Gas6/MerTK signaling pathway as a mechanism
behind nerve protection in preclinical models. Neither study is the final word,
and neither replaces the guidance of an oncology team. But together, they add
real mechanistic weight to something patients have anecdotally reported for
years: that certain marine bioactives seem to ease the collateral damage of
treatment, not just its intended target.
There's a second thread worth pulling, too.
Other 2025 research explored fucoidan's role alongside CAR-T cell therapy,
finding that it appeared to enhance anti-tumor activity in models of
non-Hodgkin lymphoma through STAT3 pathway activation. It's an early,
laboratory-stage finding — but it points to where the science is heading:
fucoidan not as a stand-alone treatment, but as a well-studied adjunct that may
support the body through the rigors of modern cancer therapy, from the
treatment itself to the side effects that follow it.
Why Hi-Q
Hi-Q's Oligo Fucoidan is extracted from Laminaria japonica (Saccharina japonica) sustainably cultivated in the cold, clean coastal waters of Matsu, Taiwan and Goheung County, South Korea. The low-temperature aqueous extraction process preserves bioactive integrity without organic solvents. All products are produced in ISO 22000 and HACCP-certified facilities and are HALAL certified.
For patients navigating chemotherapy, and for the practitioners who support them, the goal is the same: getting through treatment, maintaining quality of life, and building the physiological foundation to recover well. Fucoidan research suggests it may be a meaningful part of that support.
→ Learn about ONCOFUCO | Talk to our B2B team
References
• "Fucoidan potentiates anti-tumor efficacy of CAR-T cells against non-Hodgkin lymphoma by activation of STAT3 pathway" — Journal of Translational Medicine, 2025: https://pubmed.ncbi.nlm.nih.gov/?term=Fucoidan+potentiates+anti-tumor+efficacy+of+CAR-T+cells+non-Hodgkin+lymphoma+STAT3
• "Fucoidan reduces NET accumulation and alleviates chemotherapy-induced peripheral neuropathy" — Journal of Neuroinflammation, 2025: https://pubmed.ncbi.nlm.nih.gov/?term=Fucoidan+reduces+NET+accumulation+alleviates+chemotherapy-induced+peripheral+neuropathy
• "Fucoidan Alleviates Chemotherapy-Induced Peripheral Neuropathy via Activating the Gas6/MerTK Signaling Pathway" — Journal of Agricultural and Food Chemistry, 2025: https://pubmed.ncbi.nlm.nih.gov/?term=Fucoidan+Alleviates+Chemotherapy-Induced+Peripheral+Neuropathy+Gas6+MerTK
*This article is for informational and B2B educational purposes only and does not constitute medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Related Hi-Q Products
